Cell Therapy from the UK Fights Cardiovascular Disease

We’ve decided to start this year’s tour of European biotechs in London, an exciting place full of opportunities for biotech entrepreneurs. Rexgenero, working in cell therapy, chose the busy capital to establish its offices.

rexgenero logo

City: London, UK

Founded: 2014

Employees: 11-50

Financial data: N/A

Joe Dupere, CEO

Joe Dupere, CEO

Mission: Rexgenero develops cell therapies focused on severe diseases for which no effective treatments are currently available. In particular, the company currently is testing in the clinic three products using bone marrow cells to treat critical limb ischemia (CLI) in both diabetic and non-diabetic patients. The most advanced one, REX-001, is now preparing to enter Phase III.

Although based in the UK, the company has R&D and manufacturing facilities in Sevilla, Spain. There, the company collaborates with license partners from the Andalusian public health system.

Comment: if Rexgenero manages to make it to the market, it could make a big profit: the global CLI market is currently valued at €11B ($12B). However, we couldn’t find any financial data or details on the results from its trials, so it’s difficult to evaluate how likely the company is to eventually launch its products and disrupt the market.



Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.